Guided Therapeutics (GTHP) 0.4700 $GTHP
Guided Therapeutics Receives May 8th Meeting Date from FDA to Discuss LuViva(R) Advanced Cervical Scan PMA Application
Business Wire - Thu Apr 10, 7:59AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the company has been given a face-to-face meeting date of May 8, 2014, by the U.S. Food and Drug Administration (FDA), to discuss the company's response to the September 6, 2013 not-approvable letter that the company received from the agency.
Guided Therapeutics' LuViva(R) Honored as Finalist in the Medical Device Excellence Awards
Business Wire - Wed Apr 09, 7:59AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), today announced that the LuViva(R) Advanced Cervical Scan, its non-invasive device used to detect cervical disease instantly at the point of care, has been selected as a finalist in the Hospital Devices and Therapeutic Products' category of the 17th Annual Medical Device Excellence Awards (MDEA) competition. Selected products excel in the areas of product innovation, design and engineering achievement, end-user benefit, and cost-effectiveness in manufacturing and healthcare delivery. Winners will be announced at the 2014 MDEA Ceremony held Wednesday, June 11, 2014 in conjunction with the MD&M East event at the Jacob K. Javits Convention Center in New York.
Guided Therapeutics Submits Request for Face to Face Meeting with FDA; Receives Notification on PMA Extension for LuViva(R) Advanced Cervical Scan
Business Wire - Thu Mar 27, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the company has submitted a letter requesting a face-to-face meeting with the U.S. Food and Drug Administration (FDA) in the next 60 to 90 days. This letter is in response to the September 6, 2013 letter that the company received from the FDA. Additionally, the FDA has granted the company its requested 180 day extension on the PMA filing to allow time for the meeting to occur.
Guided Therapeutics Reports Fourth Quarter and 2013 Results
Business Wire - Wed Mar 26, 3:44PM CDT
--LuViva(R) Advanced Cervical Scan momentum building with key opinion leaders; increasing number of product evaluations
HPV Screening Beneficial for Guided Therapeutics' LuViva(R) Advanced Cervical Scan in Developed Countries; No Anticipated Impact in Developing Countries
Business Wire - Tue Mar 18, 7:05AM CDT
The March 12, 2014, recommendation by a U.S. Food and Drug Administration (FDA) panel to use human papillomavirus (HPV) testing as an alternative to Pap testing for screening of women for cervical cancer has the potential to increase the need for the LuViva(R) Advanced Cervical Scan in developed countries, according to Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP). As part of its CE Mark, LuViva is already approved for use in the European Union as a triage test to be used after a positive HPV test and/or a positive Pap test.
Guided Therapeutics to Report Fourth Quarter 2013 Results and Hold Conference Call
Business Wire - Wed Mar 05, 2:40PM CST
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its fourth quarter ended December 31, 2013 on Wednesday, March 26, 2014, after the market closes.
New Clinical Study Results of Guided Therapeutics' LuViva(R) Advanced Cervical Scan to be Presented by Key Opinion Leaders at Top International Medical Conference
Business Wire - Tue Feb 18, 7:05AM CST
The Secretary General of the International Federation for Cervical Pathology and Colposcopy (IFCPC), Dr. James Bentley, will present results of a new clinical study of the LuViva(R) Advanced Cervical Scan at the 15th World Congress for Cervical Pathology and Colposcopy, being held May 26 - 30 in London. The LuViva, a non-invasive device used to detect cervical disease instantly at the point of care, is a product of Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP).
2014 Analysis of the US Hospital Cancer Diagnostics Market
M2 - Thu Feb 13, 3:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/g5hk8t/2014_analysis_of) has announced the addition of the "2014 Analysis of the US Hospital Cancer Diagnostics Market" report to their offering. This new report contains 533 pages, 43 tables, and presents a comprehensive analysis of the US hospital cancer diagnostics market, including: - Major issues pertaining to the French hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. - Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. - Test volume and sales forecasts for 40 cancer diagnostic procedures performed in French hospitals. - Current instrumentation technologies and feature comparison of leading analyzers. - Sales and market shares of leading suppliers. - Emerging diagnostic technologies and their potential market applications. - Product development opportunities. - Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. - Business opportunities and strategic recommendations for suppliers. Key Topics Covered: Introduction Worldwide Market and Technology Overview A. Cancer Statistics and Etiology B. Major Current And Emerging Cancer Diagnostic Tests C. Instrumentation Review And Market Needs D. Current and Emerging Technologies US A. Executive Summary B. Business Environment C. Market Structure D. Market Size, Growth and Major Suppliers Major Product Development Opportunities A. Reagent Kits and Test Systems/Panels B. Instrumentation C. Computers, Software and Automation D. Auxiliary Products Design Criteria for Decentralized Testing Products Alternative Market Penetration Strategies A. Internal Development B. Collaborative Arrangements C. University Contracts D. Distribution Strategies 1. Marketing Approaches 2. Product Complexity 3. Customer Preference 4. Established Suppliers 5. Emerging Suppliers 6. Major Types of Distributors 7. Market Segmentation Factor Potential Market Entry Barriers and Risks A. Market Maturity B. Cost Containment C. Competition D. Technological Edge and Limitations E. Patent Protection F. Regulatory Constraints G. Decentralized Testing Market Challenges Companies Mentioned: - Abbott - AdnaGen - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - Cepheid - Correlogic Systems - Dako - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Enterix - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Otho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/g5...nalysis_of
2014 Analysis of the World Cancer Diagnostic Testing Market: Country Segment Forecasts, Market Shares, Emerging Technologies, Competitive Strategies, Growth Opportunities
M2 - Mon Feb 10, 2:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/r66j8d/2014_analysis_of) has announced the addition of the "2014 Analysis of the World Cancer Diagnostic Testing Market: Country Segment Forecasts, Market Shares, Emerging Technologies, Competitive Strategies, Growth Opportunities" report to their offering. This new report contains 1,200 pages, 450 tables and provides forecasts for 40 tumor markers by country and market segment, as well as sales and market shares for reagent and instrument suppliers. The report is available by region, country, section, market segment and individual test: Regions: Global, Europe Countries: France, Germany, Italy, Japan, Spain, UK, USA Sections: Assays, Competitors, Instrumentation, Technologies Market Segments: Hospitals (France, Germany, Italy, Japan, Spain, UK, USA), Personalized Testing Tests: AFP, Beta-2 Microglobulin,CA Tumor Markers, CEA, Cell Surface Markers, Occult Blood, PAP, Pap Smear/HPV, PSA To purchase a DataPack that includes (test volumes, sales forecasts, supplier shares) please E-mail us. Key Topics Covered: Introduction Worldwide Market and Technology Overview A. Cancer Statistics and Etiology B. Major Current And Emerging Cancer Diagnostic Tests C. Instrumentation Review And D. Current and Emerging Technologies Competitive Profiles - Abbott - AdnaGen - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - Biomedical Diagnostics - Cepheid - Correlogic Systems - Dako - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Enterix - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Otho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila - bioMerieux For more information visit http://www.researchandmarkets.com/research/r6...nalysis_of About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Niko Receives Conversion Notice
Marketwire - Thu Jan 09, 5:01PM CST
Niko Resources Ltd. (TSX: NKO) announces that on January 8, 2014, it received a notice of conversion in accordance with the terms of the amended and restated 7% senior unsecured notes due July 13, 2014 (the "Notes"
to convert approximately US$0.25 million of the Notes. The conversion will result in the issuance of 120,904 common shares to a holder of the Notes and the outstanding principal balance of the Notes will be approximately US$8.3 million.
Guided Therapeutics Names Gene Cartwright as Chief Executive Officer
Business Wire - Tue Jan 07, 7:04AM CST
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), the maker of the LuViva(R) Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly at the point of care, today announced the appointment of Gene Cartwright, 59, as Chief Executive Officer, effective January 6, 2014. Mr. Cartwright replaces Mark L. Faupel, who has transitioned to the role of Chief Scientific Officer.
Global Point of Care (PoC) Diagnostic Testing: World Market Report 2013
M2 - Tue Dec 17, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/b8xvhg/point_of_care) has announced the addition of the "Global Point of Care (PoC) Diagnostic Testing: World Market Report 2013" report to their offering. Point of care testing covers: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening. "Global Point of Care (PoC) Diagnostic Testing: World Market Report 2013", describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the dollar volume of point of care sales and makes five year projections both in the U.S. and worldwide - including Europe, Asia and Latin America. It also examines in detail the point of care sector for 25 individual country markets. Key Topics Covered: 1. Overview 2. Overview of Diagnostic Testing Point of Care Markets 3. Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share 4. Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share 5. Analysis of the European POCT Market: Value, Growth Rates and Market Shares 6. Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market Share 7. Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share 8. Review of the Market Segments, Reagents and Equipment 9. POCT: Growth Regulators 10. Business Trends in the POC Sector 11. Technology Platform Innovations in POCT 12. Data Management and Connectivity 13. Corporate Profiles 14. POCT Sector Trends and Forecasts 15. New Entrants to the Point of Care Market Companies Mentioned: - Axxin - Biosensia Ltd - Curetis AG - DxNA, LLC - Exalenz Bioscience - Guided Therapeutics, Inc - Home Diagnostics - International Technidyne Corporation - Johnson & Johnson - LifeSign, LLC - Mitsubishi Kagaku Iatron - Nova Biomedical - Orion Diagnostica - Prima Biomedical Company - Quidel Corporation - Roche Diagnostics - Strategic Diagnostics - Trinity Biotech, Plc - Venaxis, Inc - Wave 80 Biosciences For more information visit http://www.researchandmarkets.com/research/b8...nt_of_care
2014 Analysis of CEA Testing Technologies and Emerging Markets Profiles Leading Suppliers and Recent Market Entrants
M2 - Mon Dec 16, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/skd2lp/2014_analysis_of) has announced the addition of the "2014 Analysis of CEA Testing Technologies and Emerging Markets" report to their offering. This report contains 250 pages, 15 tables and presents a detailed analysis of the CEA testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5- and 10-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Companies Mentioned: - Abbott - AdnaGen - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - Cepheid - Correlogic Systems - Dako - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Enterix - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/sk...nalysis_of About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2014 Analysis of Beta-2 Microglobulin Testing Technologies and Emerging Markets
M2 - Mon Dec 16, 5:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/kncmcx/2014_analysis_of) has announced the addition of the "2014 Analysis of Beta-2 Microglobulin Testing Technologies and Emerging Markets" report to their offering. This report contains 243 pages, 9 tables and presents a detailed analysis of the ss-2 Microglobulin testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5- and 10-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Companies Mentioned: - Abbott - AdnaGen - Applied Gene Technologies - Biomedical Diagnostics - bioMerieux - Bio-Rad - Cepheid - Correlogic Systems - Dako - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Zila For more information visit http://www.researchandmarkets.com/research/kn...nalysis_of About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2014 Analysis of the European Pap Smear/HPV Market Report Profiles Giants such as Becton Dickinson and Quest Diagnostics
M2 - Wed Dec 04, 8:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/pzxx2h/2014_analysis_of) has announced the addition of the "2014 Analysis of the European Pap Smear/HPV Market" report to their offering. This report presents a detailed analysis of the Pap Smear/HPV testing market in Europe (France, Germany, Italy, Spain, UK), including clinical significance and current laboratory practice; as well as five-year test volume and sales forecasts by country and market segment. The report examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. Companies Mentioned: -Abbott -AdnaGen -Agilent Technologies -Applied Gene Technologies -Arca/Nuvelo -Beckman Coulter/Danaher -Becton Dickinson -Biomedical Diagnostics -bioMerieux -Bio-Rad -CellSearch -Cepheid -Correlogic Systems/Vermillion -Decode -Diadexus -Diagnocure -Diasorin -Eiken Chemical -Epigenomics -Enterix -Enzo Biochem -Exact Sciences -Fujirebio/Innogenetics -Guided Therapeutics -Hologic/Gen-Probe -Kreatech -Kyowa Medex -Life Technologies -Mackay Life Sciences -Myriad Genetics -Nanogen Elitech -OncoLab -Ortho-Clinical Diagnostics -Panacea Pharmaceuticals -Polartechnics -Polymedco -PreMD -Qiagen/Ipsogen -Quest Diagnostics -Radient Pharmaceuticals -Roche -Scienion -Sequenom -Siemens Healthcare -Takara Bio -Targeted Diagnostics & Therapeutics -Tosoh -Veridex -Wako Pure Chemicals -Wallac/PE -Zila For more information visit http://www.researchandmarkets.com/research/pz...nalysis_of About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Guided Therapeutics Reports Third Quarter 2013 Results
Business Wire - Thu Nov 14, 7:00AM CST
--International distributors added for LuViva(R) Advanced Cervical Scan
Guided Therapeutics to Report Third Quarter 2013 Results and Hold Conference Call
Business Wire - Wed Nov 06, 3:22PM CST
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its third quarter ended September 30, 2013 on Thursday, November 14, 2013, after the market closes.
Guided Therapeutics Receives $250,000 Milestone Payment
Business Wire - Wed Oct 23, 7:32AM CDT
Guided Therapeutics, Inc., (OTCBB: GTHP) (OTCQB: GTHP), today announced that it received a $250,000 milestone payment from Freedom Meditech, Inc., a San Diego, California based ophthalmic medical device company. The payment was received as part of an agreement under which Guided Therapeutics licensed certain of its non-core intellectual property to Freedom Meditech for technology development related to scanning optical properties of the lens of the eye.
Guided Therapeutics Receives Additional Questions from FDA for LuViva(R) Advanced Cervical Scan
Business Wire - Mon Sep 09, 6:00AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the company received additional questions from the U.S. Food and Drug Administration (FDA) regarding the pre-market approval application for the LuViva(R) Advanced Cervical Scan. FDA advised the company the PMA was not yet approvable in its current form and that the company needed to address these questions in order to place the PMA in approvable form.
Guided Therapeutics Reports Second Quarter 2013 Results
Business Wire - Wed Aug 14, 3:05PM CDT
--LuViva(R) Advanced Cervical Scan international launch expanding
Guided Therapeutics Receives May 8th Meeting Date from FDA to Discuss LuViva(R) Advanced Cervical Scan PMA Application
Business Wire - Thu Apr 10, 7:59AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the company has been given a face-to-face meeting date of May 8, 2014, by the U.S. Food and Drug Administration (FDA), to discuss the company's response to the September 6, 2013 not-approvable letter that the company received from the agency.
Guided Therapeutics' LuViva(R) Honored as Finalist in the Medical Device Excellence Awards
Business Wire - Wed Apr 09, 7:59AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), today announced that the LuViva(R) Advanced Cervical Scan, its non-invasive device used to detect cervical disease instantly at the point of care, has been selected as a finalist in the Hospital Devices and Therapeutic Products' category of the 17th Annual Medical Device Excellence Awards (MDEA) competition. Selected products excel in the areas of product innovation, design and engineering achievement, end-user benefit, and cost-effectiveness in manufacturing and healthcare delivery. Winners will be announced at the 2014 MDEA Ceremony held Wednesday, June 11, 2014 in conjunction with the MD&M East event at the Jacob K. Javits Convention Center in New York.
Guided Therapeutics Submits Request for Face to Face Meeting with FDA; Receives Notification on PMA Extension for LuViva(R) Advanced Cervical Scan
Business Wire - Thu Mar 27, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the company has submitted a letter requesting a face-to-face meeting with the U.S. Food and Drug Administration (FDA) in the next 60 to 90 days. This letter is in response to the September 6, 2013 letter that the company received from the FDA. Additionally, the FDA has granted the company its requested 180 day extension on the PMA filing to allow time for the meeting to occur.
Guided Therapeutics Reports Fourth Quarter and 2013 Results
Business Wire - Wed Mar 26, 3:44PM CDT
--LuViva(R) Advanced Cervical Scan momentum building with key opinion leaders; increasing number of product evaluations
HPV Screening Beneficial for Guided Therapeutics' LuViva(R) Advanced Cervical Scan in Developed Countries; No Anticipated Impact in Developing Countries
Business Wire - Tue Mar 18, 7:05AM CDT
The March 12, 2014, recommendation by a U.S. Food and Drug Administration (FDA) panel to use human papillomavirus (HPV) testing as an alternative to Pap testing for screening of women for cervical cancer has the potential to increase the need for the LuViva(R) Advanced Cervical Scan in developed countries, according to Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP). As part of its CE Mark, LuViva is already approved for use in the European Union as a triage test to be used after a positive HPV test and/or a positive Pap test.
Guided Therapeutics to Report Fourth Quarter 2013 Results and Hold Conference Call
Business Wire - Wed Mar 05, 2:40PM CST
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its fourth quarter ended December 31, 2013 on Wednesday, March 26, 2014, after the market closes.
New Clinical Study Results of Guided Therapeutics' LuViva(R) Advanced Cervical Scan to be Presented by Key Opinion Leaders at Top International Medical Conference
Business Wire - Tue Feb 18, 7:05AM CST
The Secretary General of the International Federation for Cervical Pathology and Colposcopy (IFCPC), Dr. James Bentley, will present results of a new clinical study of the LuViva(R) Advanced Cervical Scan at the 15th World Congress for Cervical Pathology and Colposcopy, being held May 26 - 30 in London. The LuViva, a non-invasive device used to detect cervical disease instantly at the point of care, is a product of Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP).
2014 Analysis of the US Hospital Cancer Diagnostics Market
M2 - Thu Feb 13, 3:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/g5hk8t/2014_analysis_of) has announced the addition of the "2014 Analysis of the US Hospital Cancer Diagnostics Market" report to their offering. This new report contains 533 pages, 43 tables, and presents a comprehensive analysis of the US hospital cancer diagnostics market, including: - Major issues pertaining to the French hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. - Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. - Test volume and sales forecasts for 40 cancer diagnostic procedures performed in French hospitals. - Current instrumentation technologies and feature comparison of leading analyzers. - Sales and market shares of leading suppliers. - Emerging diagnostic technologies and their potential market applications. - Product development opportunities. - Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. - Business opportunities and strategic recommendations for suppliers. Key Topics Covered: Introduction Worldwide Market and Technology Overview A. Cancer Statistics and Etiology B. Major Current And Emerging Cancer Diagnostic Tests C. Instrumentation Review And Market Needs D. Current and Emerging Technologies US A. Executive Summary B. Business Environment C. Market Structure D. Market Size, Growth and Major Suppliers Major Product Development Opportunities A. Reagent Kits and Test Systems/Panels B. Instrumentation C. Computers, Software and Automation D. Auxiliary Products Design Criteria for Decentralized Testing Products Alternative Market Penetration Strategies A. Internal Development B. Collaborative Arrangements C. University Contracts D. Distribution Strategies 1. Marketing Approaches 2. Product Complexity 3. Customer Preference 4. Established Suppliers 5. Emerging Suppliers 6. Major Types of Distributors 7. Market Segmentation Factor Potential Market Entry Barriers and Risks A. Market Maturity B. Cost Containment C. Competition D. Technological Edge and Limitations E. Patent Protection F. Regulatory Constraints G. Decentralized Testing Market Challenges Companies Mentioned: - Abbott - AdnaGen - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - Cepheid - Correlogic Systems - Dako - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Enterix - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Otho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/g5...nalysis_of
2014 Analysis of the World Cancer Diagnostic Testing Market: Country Segment Forecasts, Market Shares, Emerging Technologies, Competitive Strategies, Growth Opportunities
M2 - Mon Feb 10, 2:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/r66j8d/2014_analysis_of) has announced the addition of the "2014 Analysis of the World Cancer Diagnostic Testing Market: Country Segment Forecasts, Market Shares, Emerging Technologies, Competitive Strategies, Growth Opportunities" report to their offering. This new report contains 1,200 pages, 450 tables and provides forecasts for 40 tumor markers by country and market segment, as well as sales and market shares for reagent and instrument suppliers. The report is available by region, country, section, market segment and individual test: Regions: Global, Europe Countries: France, Germany, Italy, Japan, Spain, UK, USA Sections: Assays, Competitors, Instrumentation, Technologies Market Segments: Hospitals (France, Germany, Italy, Japan, Spain, UK, USA), Personalized Testing Tests: AFP, Beta-2 Microglobulin,CA Tumor Markers, CEA, Cell Surface Markers, Occult Blood, PAP, Pap Smear/HPV, PSA To purchase a DataPack that includes (test volumes, sales forecasts, supplier shares) please E-mail us. Key Topics Covered: Introduction Worldwide Market and Technology Overview A. Cancer Statistics and Etiology B. Major Current And Emerging Cancer Diagnostic Tests C. Instrumentation Review And D. Current and Emerging Technologies Competitive Profiles - Abbott - AdnaGen - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - Biomedical Diagnostics - Cepheid - Correlogic Systems - Dako - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Enterix - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Otho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila - bioMerieux For more information visit http://www.researchandmarkets.com/research/r6...nalysis_of About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Niko Receives Conversion Notice
Marketwire - Thu Jan 09, 5:01PM CST
Niko Resources Ltd. (TSX: NKO) announces that on January 8, 2014, it received a notice of conversion in accordance with the terms of the amended and restated 7% senior unsecured notes due July 13, 2014 (the "Notes"
to convert approximately US$0.25 million of the Notes. The conversion will result in the issuance of 120,904 common shares to a holder of the Notes and the outstanding principal balance of the Notes will be approximately US$8.3 million. Guided Therapeutics Names Gene Cartwright as Chief Executive Officer
Business Wire - Tue Jan 07, 7:04AM CST
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), the maker of the LuViva(R) Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly at the point of care, today announced the appointment of Gene Cartwright, 59, as Chief Executive Officer, effective January 6, 2014. Mr. Cartwright replaces Mark L. Faupel, who has transitioned to the role of Chief Scientific Officer.
Global Point of Care (PoC) Diagnostic Testing: World Market Report 2013
M2 - Tue Dec 17, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/b8xvhg/point_of_care) has announced the addition of the "Global Point of Care (PoC) Diagnostic Testing: World Market Report 2013" report to their offering. Point of care testing covers: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening. "Global Point of Care (PoC) Diagnostic Testing: World Market Report 2013", describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the dollar volume of point of care sales and makes five year projections both in the U.S. and worldwide - including Europe, Asia and Latin America. It also examines in detail the point of care sector for 25 individual country markets. Key Topics Covered: 1. Overview 2. Overview of Diagnostic Testing Point of Care Markets 3. Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share 4. Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share 5. Analysis of the European POCT Market: Value, Growth Rates and Market Shares 6. Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market Share 7. Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share 8. Review of the Market Segments, Reagents and Equipment 9. POCT: Growth Regulators 10. Business Trends in the POC Sector 11. Technology Platform Innovations in POCT 12. Data Management and Connectivity 13. Corporate Profiles 14. POCT Sector Trends and Forecasts 15. New Entrants to the Point of Care Market Companies Mentioned: - Axxin - Biosensia Ltd - Curetis AG - DxNA, LLC - Exalenz Bioscience - Guided Therapeutics, Inc - Home Diagnostics - International Technidyne Corporation - Johnson & Johnson - LifeSign, LLC - Mitsubishi Kagaku Iatron - Nova Biomedical - Orion Diagnostica - Prima Biomedical Company - Quidel Corporation - Roche Diagnostics - Strategic Diagnostics - Trinity Biotech, Plc - Venaxis, Inc - Wave 80 Biosciences For more information visit http://www.researchandmarkets.com/research/b8...nt_of_care
2014 Analysis of CEA Testing Technologies and Emerging Markets Profiles Leading Suppliers and Recent Market Entrants
M2 - Mon Dec 16, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/skd2lp/2014_analysis_of) has announced the addition of the "2014 Analysis of CEA Testing Technologies and Emerging Markets" report to their offering. This report contains 250 pages, 15 tables and presents a detailed analysis of the CEA testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5- and 10-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Companies Mentioned: - Abbott - AdnaGen - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - Cepheid - Correlogic Systems - Dako - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Enterix - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/sk...nalysis_of About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2014 Analysis of Beta-2 Microglobulin Testing Technologies and Emerging Markets
M2 - Mon Dec 16, 5:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/kncmcx/2014_analysis_of) has announced the addition of the "2014 Analysis of Beta-2 Microglobulin Testing Technologies and Emerging Markets" report to their offering. This report contains 243 pages, 9 tables and presents a detailed analysis of the ss-2 Microglobulin testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5- and 10-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Companies Mentioned: - Abbott - AdnaGen - Applied Gene Technologies - Biomedical Diagnostics - bioMerieux - Bio-Rad - Cepheid - Correlogic Systems - Dako - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Zila For more information visit http://www.researchandmarkets.com/research/kn...nalysis_of About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2014 Analysis of the European Pap Smear/HPV Market Report Profiles Giants such as Becton Dickinson and Quest Diagnostics
M2 - Wed Dec 04, 8:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/pzxx2h/2014_analysis_of) has announced the addition of the "2014 Analysis of the European Pap Smear/HPV Market" report to their offering. This report presents a detailed analysis of the Pap Smear/HPV testing market in Europe (France, Germany, Italy, Spain, UK), including clinical significance and current laboratory practice; as well as five-year test volume and sales forecasts by country and market segment. The report examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. Companies Mentioned: -Abbott -AdnaGen -Agilent Technologies -Applied Gene Technologies -Arca/Nuvelo -Beckman Coulter/Danaher -Becton Dickinson -Biomedical Diagnostics -bioMerieux -Bio-Rad -CellSearch -Cepheid -Correlogic Systems/Vermillion -Decode -Diadexus -Diagnocure -Diasorin -Eiken Chemical -Epigenomics -Enterix -Enzo Biochem -Exact Sciences -Fujirebio/Innogenetics -Guided Therapeutics -Hologic/Gen-Probe -Kreatech -Kyowa Medex -Life Technologies -Mackay Life Sciences -Myriad Genetics -Nanogen Elitech -OncoLab -Ortho-Clinical Diagnostics -Panacea Pharmaceuticals -Polartechnics -Polymedco -PreMD -Qiagen/Ipsogen -Quest Diagnostics -Radient Pharmaceuticals -Roche -Scienion -Sequenom -Siemens Healthcare -Takara Bio -Targeted Diagnostics & Therapeutics -Tosoh -Veridex -Wako Pure Chemicals -Wallac/PE -Zila For more information visit http://www.researchandmarkets.com/research/pz...nalysis_of About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Guided Therapeutics Reports Third Quarter 2013 Results
Business Wire - Thu Nov 14, 7:00AM CST
--International distributors added for LuViva(R) Advanced Cervical Scan
Guided Therapeutics to Report Third Quarter 2013 Results and Hold Conference Call
Business Wire - Wed Nov 06, 3:22PM CST
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its third quarter ended September 30, 2013 on Thursday, November 14, 2013, after the market closes.
Guided Therapeutics Receives $250,000 Milestone Payment
Business Wire - Wed Oct 23, 7:32AM CDT
Guided Therapeutics, Inc., (OTCBB: GTHP) (OTCQB: GTHP), today announced that it received a $250,000 milestone payment from Freedom Meditech, Inc., a San Diego, California based ophthalmic medical device company. The payment was received as part of an agreement under which Guided Therapeutics licensed certain of its non-core intellectual property to Freedom Meditech for technology development related to scanning optical properties of the lens of the eye.
Guided Therapeutics Receives Additional Questions from FDA for LuViva(R) Advanced Cervical Scan
Business Wire - Mon Sep 09, 6:00AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the company received additional questions from the U.S. Food and Drug Administration (FDA) regarding the pre-market approval application for the LuViva(R) Advanced Cervical Scan. FDA advised the company the PMA was not yet approvable in its current form and that the company needed to address these questions in order to place the PMA in approvable form.
Guided Therapeutics Reports Second Quarter 2013 Results
Business Wire - Wed Aug 14, 3:05PM CDT
--LuViva(R) Advanced Cervical Scan international launch expanding
